The two ticagrelor doses each reduced , as compared with placebo , the rate of the primary efficacy end point , with Kaplan-Meier rates at 3 years of 7.85 % in the group that received 90 mg of ticagrelor twice daily , 7.77 % in the group that received 60 mg of ticagrelor twice daily , and 9.04 % in the placebo group ( hazard ratio for 90 mg of ticagrelor vs. placebo , 0.85 ; 95 % confidence interval [ CI ] , 0.75 to 0.96 ; P = 0.008 ; hazard ratio for 60 mg of ticagrelor vs. placebo , 0.84 ; 95 % CI , 0.74 to 0.95 ; P = 0.004 ) .
